Skip to content


  • Meeting abstract
  • Open Access

New methods of nuclear medicine in thyroid

  • 1
Thyroid Research20158 (Suppl 1) :A14

  • Published:


  • Peptide
  • Glucagon
  • Thyroid Cancer
  • Hyperthyroidism
  • Molecular Imaging

Since radioiodine was first introduced in the therapy of hyperthyroidism in the 1940s, in the 21st century, thyroid has become the arena of development of nuclear-molecular biology imaging. SPECT and PET technics allow the visualization of small particles like peptides and their receptors. In PET with 18F-FDG we can assess metabolic activity of thyroid tumours. If there is higher metabolic activity, the tumour is more aggressive and the prognosis poorer. These novel methods let us observe the primary lesion and metastatic processes in iodine avid differentiated thyroid cancer (DTC) and medullary thyroid cancer (MTC). Potentially, each particle triggered with a radioisotope which is involved in a cell structure and/or its metabolism can be useful in molecular imaging. The first group of molecules used in radioisotope molecular imaging is peptide receptors agonists and antagonists. Somatostatin receptors are overexpressed in DTC and MTC. Therefore, somatostatin analogues triggered with radioisotopes are used in either imaging (99mTechnetium, 111Indium, 68Gallium) or treatment (90Yttrium, 177Lutetium) of these malignancies. Implementation of appropriate chelator allowed the creation of radiopharmaceuticals conjugated with either SPECT or PET isotopes. It seems that the best method for visualization of MTC is PET with 18F-DOPA up till now. Recently, new radiolabelled tracers for MTC visualizations are under investigation: cholecystokinin – 2 (CKK-2) gastrin receptor ligand radiolabelled with 111Indium and glucagon – like peptide -1 (GLP – 1) labelled with 99mTechnetium.

Authors’ Affiliations

Military Institute of Medicine, Warsaw, Poland


  1. Pepe G, Moncayo R, Bombardieri E, Chiti A: Somatostatin receptor SPECT. Eur J Nucl Med Mol Imaging 2012,39(Suppl 1):S41-S51.PubMedView ArticleGoogle Scholar
  2. Wild D, Fani M, Behe M, Brink I, Rivier JE, Reubi JC, et al.: First clinical evidence that imaging with somatostatin receptor antagonists is feasible. J Nucl Med 2011,52(9):1412–1417. 10.2967/jnumed.111.088922PubMedView ArticleGoogle Scholar
  3. Wang X, Fani M, Schulz S, Rivier J, Reubi JC, Maecke HR: Comprehensive evaluation of a somatostatin-based radiolabelled antagonist for diagnostic imaging and radionuclide therapy. Eur J Nucl Med Mol Imaging 2012,39(12):1876–1885. 10.1007/s00259-012-2231-8PubMedView ArticleGoogle Scholar
  4. Ambrosini V, Fani M, Fanti S, Forrer F, Maecke HR: Radiopeptide Imaging and Therapy in Europe. J Nucl Med 2011,52(Suppl 2):42S-55S.PubMedView ArticleGoogle Scholar
  5. Fani M, Maecke HR, Okavi SM: Radiolabeled peptides: Valuable tools for the detection and treatment of cancer. Theranostics 2012,2(5):481–501. 10.7150/thno.4024PubMed CentralPubMedView ArticleGoogle Scholar
  6. Pach D, Sowa-Staszczak A, Jabrocka-Hybel A, Stefańska A, Tomaszuk M, Mikołajczak R, et al.: Glucagon-like peptide-1 Receptor Imaging with [Lys Ahx-HYNIC- 99mTc(EDDA)NH2]-Exendin- 4 for the medullary Thyroid Cancer. Int J Endocrinol 2013, 2013: 481–501.View ArticleGoogle Scholar


© Kaminski; licensee BioMed Central Ltd. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.